Relationship Between Plasma Concentrations of 5-Fluorouracil and 5-Fluoro-5,6-Dihydrouracil and Toxicity of 5-Fluorouracil Infusions in Cancer Patients
- 1 October 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 24 (5) , 588-593
- https://doi.org/10.1097/00007691-200210000-00002
Abstract
This study investigated the relationship among the pharmacokinetics of 5-fluorouracil (5-FU) and 5-fluoro-5,6-dihydrouracil (5-FDHU); the activity of dihydropyrimidine dehydrogenase (DPD) in peripheral blood mononuclear cells; and treatment-related toxicity in 26 patients with surgically resected colorectal cancer treated with short daily infusions of 5-FU adjuvant chemotherapy, each cycle consisting of 5 consecutive days every 4 weeks. After the first chemotherapeutic cycle, severe stomatitis and diarrhea occurred in 5 patients and were related to the variations in the systemic disposition of the drug rather than to DPD activity. These patients showed a significant decrease in 5-FU clearance, and an increase in the 5-FU/5-FDHU area under the time-concentration curve (AUC) ratio, as compared with patients who experienced mild toxicities, whereas a low DPD activity was observed in only 2 patients. In conclusion, the results of this study demonstrate that the alterations in 5-FU and 5-FDHU pharmacokinetics are related to severe toxicities in patients treated with short intravenous infusion of 5-FU.Keywords
This publication has 19 references indexed in Scilit:
- Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patientsAnnals of Oncology, 2001
- Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trialThe Lancet, 2000
- Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU DosageJournal of Clinical Oncology, 1999
- Can Pharmacokinetic Monitoring Improve Clinical Use of Fluorouracil?Clinical Pharmacokinetics, 1999
- Putative Role of Dihydropyrimidine Dehydrogenase in the Toxic Side Effect of 5-Fluorouracil in Colorectal Cancer PatientsOncology, 1998
- Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival.Journal of Clinical Oncology, 1997
- Individualizing Therapy with 5-Fluorouracil Related to Dihydropyrimidine Dehydrogenase: Theory and LimitsTherapeutic Drug Monitoring, 1996
- Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicitiesThe American Journal of Medicine, 1995
- Clinical Pharmacology of 5-FluorouracilClinical Pharmacokinetics, 1989
- Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patientsEuropean Journal of Clinical Pharmacology, 1987